Nafronyl Oxalate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561230

CAS#: 3200-06-4

Description: Nafronyl Oxalate is a a selective antagonist of 5-HT2 receptors. Nafronyl Oxalate is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity.


Price and Availability

Size
Price

5g
USD 210
Size
Price

Size
Price

Nafronyl Oxalate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561230
Name: Nafronyl Oxalate
CAS#: 3200-06-4
Chemical Formula: C26H35NO7
Exact Mass:
Molecular Weight: 473.57
Elemental Analysis: C, 65.94; H, 7.45; N, 2.96; O, 23.65


Synonym: Nafronyl Oxalate; Dubimax: Dusodril: Naftidrofuryl oxalate; Naphtidrofuryl oxalate; Praxilene

IUPAC/Chemical Name: 2-(Diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate Oxalate

InChi Key: SSAJNPNVUYMUCI-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H33NO3.C2H2O4/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;3-1(4)2(5)6/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;(H,3,4)(H,5,6)

SMILES Code: O=C(OCCN(CC)CC)C(CC1=C2C=CC=CC2=CC=C1)CC3OCCC3.O=C(O)C(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. doi: 10.3310/hta15400. Review. PubMed PMID: 22142554; PubMed Central PMCID: PMC4781353.

2: Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-8. doi: 10.1002/bjs.8895. Epub 2012 Oct 3. Review. PubMed PMID: 23034699.

3: Hong H, Mackey WC. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther. 2014 Aug 1;36(8):1290-301. doi: 10.1016/j.clinthera.2014.06.010. Epub 2014 Jul 8. Review. PubMed PMID: 25012728.

4: Marcial JM, Pérez R, Vargas P, Franqui-Rivera H. Non-Invasive Therapy of Peripheral Arterial Disease. Bol Asoc Med P R. 2015 Jul-Sep;107(3):52-7. Review. PubMed PMID: 26742197.

5: Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Büller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999 Feb 22;159(4):337-45. Review. PubMed PMID: 10030306.

6: de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012 Dec 12;12:CD001368. doi: 10.1002/14651858.CD001368.pub4. Review. PubMed PMID: 23235580.

7: Kuznetsov MR, Kosykh IV, Iumin SM, Kunitsyn NV, Kuznetsova VF, Tolstikhin VIu, Magnitskiĭ LA. [Use of naftidrofuryl in angiology]. Angiol Sosud Khir. 2014;20(4):27-35. Review. Russian. PubMed PMID: 25490354.

8: Melzer J, Saller R. [Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review]. Forsch Komplementmed. 2013;20 Suppl 2:17-21. doi: 10.1159/000351720. Epub 2013 Jun 14. Review. German. PubMed PMID: 23860108.

9: Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010 Feb 23;74(8):691-6. doi: 10.1212/WNL.0b013e3181d0ccca. Review. PubMed PMID: 20177124.

10: Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging. 2005;22(11):967-77. Review. PubMed PMID: 16323973.

11: Smith FB, Bradbury A, Fowkes G. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002070. doi: 10.1002/14651858.CD002070.pub2. Review. PubMed PMID: 22786478.

12: Hazell JW. Tinnitus. Br J Hosp Med. 1979 Nov;22(5):468-71. Review. PubMed PMID: 395984.

13: Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD002955. doi: 10.1002/14651858.CD002955.pub4. Review. PubMed PMID: 22161372.

14: Li W, Cao LX, Li GR, Jin WJ. [Applications of phosphorimetry in pharmaceutical analysis]. Guang Pu Xue Yu Guang Pu Fen Xi. 2002 Jun;22(3):518-22. Review. Chinese. PubMed PMID: 12938353.

15: Cook P, James I. Drug therapy: cerebral vasodilators (first of two parts). N Engl J Med. 1981 Dec 17;305(25):1508-13. Review. PubMed PMID: 7029283.

16: Norris CH. Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy. Drugs. 1988 Dec;36(6):754-72. Review. PubMed PMID: 3065060.

17: Butler JV, Mulkerrin EC, O'Keeffe ST. Nocturnal leg cramps in older people. Postgrad Med J. 2002 Oct;78(924):596-8. Review. PubMed PMID: 12415081; PubMed Central PMCID: PMC1742527.

18: Heidrich H. [Peripheral arterial occlusions. Principles, possibilities and limits of conservative therapy]. ZFA (Stuttgart). 1981 Apr 10;57(10):742-50. Review. German. PubMed PMID: 6165157.

19: Naftidrofuryl (Praxilene). Drug Ther Bull. 1988 Apr 5;26(7):25-7. Review. PubMed PMID: 3286179.

20: De Backer T, Vander Stichele R, De Buyzere M, De Backer G, Van Bortel L. Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. Curr Vasc Pharmacol. 2010 May;8(3):383-7. Review. PubMed PMID: 19485897.